Monitoring of serum markers for fibrosis during CCl4-induced liver damage. Effects of anti-fibrotic agents.
Liver fibrosis was induced in rats by repeated peritoneal injections of carbon tetrachloride (CCl4) over a period of 2-11 weeks. Serum procollagen III peptide (SPIIINP), prolidase (SP) and alanine aminotransferase (SALT) levels were monitored during the period of induction. The extent of fibrosis was semi-quantitatively estimated after collagen staining, and the anti-fibrotic effects of 16,16-dimethyl prostaglandin E2 (DMPGE2), colchicine, and zinc sulphate were studied. SPIIINP and SP were increased the first 2 weeks after CCl4 administration and peaked at 6 weeks. Alterations in SPIIINP and SP correlated well to the semi-quantitative histological score of liver sections during the first 6 weeks, and SP was positively related to SPIIINP throughout the whole induction period. DMPGE2 decreased SPIIINP, SP and SALT significantly in addition to a markedly decreased formation of liver collagens. Colchicine had a similar but less dramatic effect, whereas zinc sulphate only reduced SPIIINP without influencing liver damage. In conclusion SPIIINP seems to be a valuable indicator of liver fibrogenesis, and SP may play a limited role in indicating accelerated collagen metabolism in the liver. DMPGE2 obviously inhibited the production of collagens induced by CCl4. Colchicine also had an apparent effect on liver fibrosis, whereas zinc sulphate merely seemed to postpone it.
Jiang
Z
Z
Department of Internal Medicine, Nanjing Railway Medical College, People's Republic of China.
You
D Y
DY
Chen
X C
XC
Wu
J
J
D015064:16,16-Dimethylprostaglandin E2 / Q000627:therapeutic use*; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001835:Body Weight / Q000187:drug effects; D002251:Carbon Tetrachloride; D003078:Colchicine / Q000627:therapeutic use*; D005260:Female; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000097:blood* / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008991:Monitoring, Physiologic / Q000379:methods*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013431:Sulfates / Q000627:therapeutic use*; D015032:Zinc / Q000627:therapeutic use*; D019287:Zinc Sulfate
D015415:Biomarkers; D013431:Sulfates; D019287:Zinc Sulfate; D002251:Carbon Tetrachloride; D015032:Zinc; D015064:16,16-Dimethylprostaglandin E2; D003078:Colchicine